Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 199267 | 5.235 |
09:34 ET | 53757 | 5.23 |
09:36 ET | 43612 | 5.16 |
09:38 ET | 61697 | 5.12 |
09:39 ET | 49931 | 5.12 |
09:41 ET | 57275 | 5.085 |
09:43 ET | 57202 | 5.13 |
09:45 ET | 47950 | 5.105 |
09:48 ET | 51103 | 5.15 |
09:50 ET | 63694 | 5.1344 |
09:52 ET | 50021 | 5.11 |
09:54 ET | 68878 | 5.125 |
09:56 ET | 62766 | 5.15 |
09:57 ET | 57527 | 5.13 |
09:59 ET | 37954 | 5.1563 |
10:01 ET | 60147 | 5.17 |
10:03 ET | 39828 | 5.185 |
10:06 ET | 18487 | 5.185 |
10:08 ET | 39908 | 5.21 |
10:10 ET | 150983 | 5.21 |
10:12 ET | 55039 | 5.21 |
10:14 ET | 140153 | 5.235 |
10:15 ET | 51903 | 5.24 |
10:17 ET | 32474 | 5.23 |
10:19 ET | 41950 | 5.205 |
10:21 ET | 36087 | 5.23 |
10:24 ET | 7223 | 5.2303 |
10:26 ET | 89221 | 5.245 |
10:28 ET | 90304 | 5.275 |
10:30 ET | 32698 | 5.265 |
10:32 ET | 789965 | 5.295 |
10:33 ET | 41443 | 5.32 |
10:35 ET | 125188 | 5.3391 |
10:37 ET | 185216 | 5.3 |
10:39 ET | 112371 | 5.265 |
10:42 ET | 34442 | 5.235 |
10:44 ET | 26038 | 5.225 |
10:46 ET | 48033 | 5.245 |
10:48 ET | 14029 | 5.235 |
10:50 ET | 27363 | 5.235 |
10:51 ET | 5530 | 5.235 |
10:53 ET | 19038 | 5.235 |
10:55 ET | 31006 | 5.245 |
10:57 ET | 58069 | 5.215 |
11:00 ET | 59808 | 5.21 |
11:02 ET | 18700 | 5.21 |
11:04 ET | 49666 | 5.221 |
11:06 ET | 39747 | 5.215 |
11:08 ET | 4124 | 5.21 |
11:09 ET | 17197 | 5.2236 |
11:11 ET | 66524 | 5.225 |
11:13 ET | 176741 | 5.25 |
11:15 ET | 150338 | 5.205 |
11:18 ET | 48144 | 5.1926 |
11:20 ET | 23885 | 5.2 |
11:22 ET | 32194 | 5.21 |
11:24 ET | 20229 | 5.205 |
11:26 ET | 2360 | 5.205 |
11:27 ET | 5269 | 5.21 |
11:29 ET | 23443 | 5.195 |
11:31 ET | 5494 | 5.195 |
11:33 ET | 27750 | 5.185 |
11:36 ET | 12076 | 5.185 |
11:38 ET | 49015 | 5.195 |
11:40 ET | 14291 | 5.205 |
11:42 ET | 6946 | 5.205 |
11:44 ET | 17043 | 5.205 |
11:45 ET | 3418 | 5.205 |
11:47 ET | 30998 | 5.19 |
11:49 ET | 6321 | 5.19 |
11:51 ET | 7725 | 5.185 |
11:54 ET | 162394 | 5.205 |
11:56 ET | 20252 | 5.2 |
11:58 ET | 28918 | 5.2015 |
12:00 ET | 9336 | 5.215 |
12:02 ET | 38437 | 5.215 |
12:03 ET | 15497 | 5.215 |
12:05 ET | 5906 | 5.215 |
12:07 ET | 49790 | 5.21 |
12:09 ET | 20890 | 5.195 |
12:12 ET | 22441 | 5.19 |
12:14 ET | 6043 | 5.195 |
12:16 ET | 46684 | 5.165 |
12:18 ET | 11905 | 5.165 |
12:20 ET | 16621 | 5.165 |
12:21 ET | 49818 | 5.155 |
12:23 ET | 30859 | 5.155 |
12:25 ET | 22978 | 5.15 |
12:27 ET | 18282 | 5.15 |
12:30 ET | 18550 | 5.145 |
12:32 ET | 28765 | 5.16 |
12:34 ET | 11416 | 5.165 |
12:36 ET | 6795 | 5.17 |
12:38 ET | 9532 | 5.17 |
12:39 ET | 6313 | 5.165 |
12:41 ET | 28479 | 5.155 |
12:43 ET | 13339 | 5.155 |
12:45 ET | 49543 | 5.15 |
12:48 ET | 4407 | 5.1488 |
12:50 ET | 6275 | 5.145 |
12:52 ET | 9650 | 5.1443 |
12:54 ET | 17753 | 5.145 |
12:56 ET | 27803 | 5.15 |
12:57 ET | 1683 | 5.1499 |
12:59 ET | 11975 | 5.145 |
01:01 ET | 15680 | 5.145 |
01:03 ET | 15226 | 5.145 |
01:06 ET | 4061 | 5.15 |
01:08 ET | 43297 | 5.125 |
01:10 ET | 5175 | 5.125 |
01:12 ET | 5432 | 5.125 |
01:14 ET | 6999 | 5.125 |
01:15 ET | 11011 | 5.115 |
01:17 ET | 18042 | 5.115 |
01:19 ET | 20493 | 5.105 |
01:21 ET | 33203 | 5.12 |
01:24 ET | 6151 | 5.115 |
01:26 ET | 16525 | 5.12 |
01:28 ET | 6181 | 5.125 |
01:30 ET | 34326 | 5.13 |
01:32 ET | 20499 | 5.115 |
01:33 ET | 4602 | 5.115 |
01:35 ET | 15382 | 5.12 |
01:37 ET | 28122 | 5.11 |
01:39 ET | 30469 | 5.12 |
01:42 ET | 11516 | 5.12 |
01:44 ET | 6432 | 5.12 |
01:46 ET | 16036 | 5.115 |
01:48 ET | 3820 | 5.115 |
01:50 ET | 4226 | 5.115 |
01:51 ET | 19718 | 5.13 |
01:53 ET | 3253 | 5.125 |
01:55 ET | 6742 | 5.13 |
01:57 ET | 8346 | 5.13 |
02:00 ET | 4902 | 5.13 |
02:02 ET | 116112 | 5.0824 |
02:04 ET | 37556 | 5.095 |
02:06 ET | 22544 | 5.105 |
02:08 ET | 12008 | 5.095 |
02:09 ET | 14370 | 5.09 |
02:11 ET | 17674 | 5.095 |
02:13 ET | 8451 | 5.095 |
02:15 ET | 14395 | 5.095 |
02:18 ET | 62796 | 5.115 |
02:20 ET | 49832 | 5.13 |
02:22 ET | 16828 | 5.12 |
02:24 ET | 24237 | 5.125 |
02:26 ET | 22224 | 5.125 |
02:27 ET | 41332 | 5.15 |
02:29 ET | 34738 | 5.135 |
02:31 ET | 28087 | 5.135 |
02:33 ET | 37777 | 5.135 |
02:36 ET | 13268 | 5.135 |
02:38 ET | 44071 | 5.1499 |
02:40 ET | 31639 | 5.16 |
02:42 ET | 27908 | 5.15 |
02:44 ET | 37958 | 5.125 |
02:45 ET | 30332 | 5.1002 |
02:47 ET | 31535 | 5.115 |
02:49 ET | 28218 | 5.1 |
02:51 ET | 14585 | 5.115 |
02:54 ET | 15942 | 5.105 |
02:56 ET | 11201 | 5.105 |
02:58 ET | 34844 | 5.125 |
03:00 ET | 32986 | 5.125 |
03:02 ET | 13688 | 5.135 |
03:03 ET | 32916 | 5.135 |
03:05 ET | 17784 | 5.115 |
03:07 ET | 32619 | 5.105 |
03:09 ET | 19225 | 5.115 |
03:12 ET | 19114 | 5.115 |
03:14 ET | 32870 | 5.115 |
03:16 ET | 43026 | 5.125 |
03:18 ET | 8350 | 5.125 |
03:20 ET | 37698 | 5.115 |
03:21 ET | 7588 | 5.115 |
03:23 ET | 45206 | 5.1 |
03:25 ET | 117344 | 5.085 |
03:27 ET | 21750 | 5.08 |
03:30 ET | 79364 | 5.05 |
03:32 ET | 149081 | 5.0799 |
03:34 ET | 31026 | 5.0899 |
03:36 ET | 45357 | 5.075 |
03:38 ET | 41581 | 5.085 |
03:39 ET | 57094 | 5.085 |
03:41 ET | 60312 | 5.0513 |
03:43 ET | 97493 | 5.045 |
03:45 ET | 24219 | 5.0401 |
03:48 ET | 84445 | 5.055 |
03:50 ET | 103095 | 5.065 |
03:52 ET | 113037 | 5.105 |
03:54 ET | 110566 | 5.125 |
03:56 ET | 229641 | 5.115 |
03:57 ET | 129177 | 5.1 |
03:59 ET | 212879 | 5.09 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 3.0B | -14.7x | --- |
Structure Therapeutics Inc | 3.0B | -22.4x | --- |
SpringWorks Therapeutics Inc | 3.0B | -7.5x | --- |
Dyne Therapeutics Inc | 3.1B | -8.3x | --- |
Xenon Pharmaceuticals Inc | 2.9B | -14.1x | --- |
Biohaven Ltd | 3.1B | -4.9x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.0B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.46 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -14.7x |
Price/Sales (TTM) | 5,748.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.